Frataxin enhancer

A symbiotic, protein technology, applied in the field of therapeutic and/or preventive agents, can solve problems such as unrealized practical application

Inactive Publication Date: 2016-07-06
TOKYO UNIVERSITY OF AGRICULTURE +1
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, strategies to enhance frataxin using HDAC inhibitors are expected to have various side effects and have not been practically implemented until now.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Frataxin enhancer
  • Frataxin enhancer
  • Frataxin enhancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0057] 1. Materials and Methods

[0058] (i) at 5% CO 2 Next, normal human fibroblast cell line WI-38 was cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS). (ii) 5-aminolevulinic acid (ALA) was added to DMEM without FBS at a final concentration of 2 mM, and the cells of (i) were incubated in the medium at 37° C. for 2 hours to allow ALA to bind . (iii) Subsequently, the cells were transferred to DMEM containing 10% FBS and incubated at 37°C for 24 hours. (iv) Cells were collected by trypsinization, washed with phosphate-buffered saline (PBS), and then suspended in SDS sample buffer (50 mM Tris-HCl, pH 6.8, 2% SDS, 2.5%-mercaptoethanol, 10% glycerol and 0.01% bromophenol blue) at 100°C for 5 minutes to dissolve. In this example, the cell lysate is referred to as "Sample 1".

[0059] As a negative control, except that the above step (ii) was different, a cell lysate was prepared by a similar preparation to sample 1, and the cell...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The purpose of the invention is to provide a drug effective in the treatment and prevention of diseases and the like caused by a decrease in frataxin production. The invention provides a frataxin enhancer containing 5-aminolevulinic acid (ALA) or a derivative thereof or a salt of these, and a therapeutic agent and / or prophylactic agent for diseases caused by a decrease in frataxin production.

Description

technical field [0001] The present invention relates to frataxin enhancers and therapeutic and / or preventive agents for diseases caused by decreased frataxin production. In particular, the present invention relates to a frataxin enhancer comprising 5-aminolevulinic acid (ALA) or a derivative thereof or a salt thereof, and a therapeutic and / or preventive agent for a disease caused by a decrease in taxin production . Background technique [0002] Freetaxin is an iron-binding protein found in mitochondria and is known to function as an iron chaperone protein in restoring aconitase activity of the citric acid cycle that is reduced by reactive oxygen species. Mutaxins are also known to be responsible for supplying iron to iron-sulfur clusters. The iron-sulfur cluster exists, for example, as the active center of aconitase, the enzyme that converts citrate to isocitrate in the mitochondrial TCA cycle, or as a component of complex I of the mitochondrial electron transport chain (...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/197A61P7/00A61P7/06A61P25/00A61P25/14A61P43/00
CPCA61K31/197A61P7/00A61P7/06A61P25/00A61P25/14A61P43/00
Inventor 千叶樱拓田中彻安部史纪中岛元夫神谷敦子芳贺直实高桥究
Owner TOKYO UNIVERSITY OF AGRICULTURE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap